Buprofezin not renewed: an endocrine disruptor for the thyroid in humans, consumer risk assessment for residues in honey and rotational crops not finalised; authorisations withdrawn by 3 June 2027, use of stocks until 3 December 2027

Commission Implementing Regulation (EU) 2026/2517, published on 13 November 2026, does not renew the approval of the active substance buprofezin and deletes it from Part A of the Annex to Implementing Regulation (EU) No 540/2011. The Commission relies on the EFSA conclusions of 16 April 2025: buprofezin meets the criteria for an endocrine disruptor with regard to the thyroid hormone modality in humans.

Source: Commission Implementing Regulation (EU) 2026/2517 of 12 November 2026 concerning the non-renewal of the approval of the active substance buprofezin, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 (OJ L, 2026/2517, 13.11.2026)

Lab-News